In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.

Back to Metastatic Trial Search
Powered by BreastCancerTrials.org

You have matched to trials (Last updated: April 17, 2021)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Genetics/Family History

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53


1

NEAREST SITE: 1814 miles
The West Clinic, P.C. ( Site 0021)
Germantown, TN

VISITS: 1 visit every week, ongoing

PHASE: I

NCT ID: NCT03396445

Two Immunotherapies and Chemotherapy for Advanced Triple Negative Breast Cancer

A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Scientific Title

Purpose
To study the safety, anti-cancer activity and side effects of giving the experimental immunotherapy MK-5890 with the immunotherapy pembrolizumab (Keytruda®) and the chemotherapy nab-paclitaxel (Abraxane®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have not already received chemotherapy for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MK-5890, by IV, every 1.5 months, ongoing</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 1.5 months, ongoing</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®), by IV, every week (3 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MK-5890 is an experimental immunotherapy that may help stimulate the immune system to go after <span class="highlight">cancer</span> cells. It is a CD27 antigen stimulant.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, it gets the immune system to go after <span class="highlight">cancer</span> cells. It is approved to treat many types of <span class="highlight">cancers</span>, including some types of <span class="highlight">breast</span> <span class="highlight">cancer</span>, but its use in this trial is considered experimental. </li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®) is a <span class="highlight">chemotherapy</span> drug routinely used to treat <span class="highlight">advanced</span> <span class="highlight">breast</span> <span class="highlight">cancer</span>.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of <span class="highlight">advanced</span> <span class="highlight">cancer</span>.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03396445' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/in-advanced-solid-tumors-mk5890-shows-promising-safety-results-as-monotherapy-or-in-combination-with-pembrolizumab' target='_blank'>Targeted Oncology: In Advanced Solid Tumors, MK-5890 Shows Promising Safety Results as Monotherapy or in Combination with Pembrolizumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/triple-negative-breast-cancer/?src=google&med=cpc&camp=Keytruda+TNBC_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=TNBC&kw=keytruda+tnbc&utm_kxconfid=ttznk4gb9&gclid=Cj0KCQiA1pyCBhCtARIsAHaY_5dvAZFxDyc_NLdQ8BmU45jQz7LkNGbiHjqmyNrwHEZhlney' target='_blank'>Merck Oncology Information Page: Keytruda® (Pembrolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/tnbc-treatment-update-2021/' target='_blank'>Metastatic Trial Talk: 2021 Update on Metastatic Triple Negative Breast Cancer Treatment</a> </li></ul>
See more